When cells matter, it is key to prioritize their care at every stage. Clear resolution and retention of rare cell populations proves to be an issue in cell therapy processing utilizing traditional centrifugation methods. Automated, reproducible sample prep that does not rely on manual handling is the missing piece to saving precious samples, time, and money.
The major key cost drivers of the autologous CAR T-cell therapy are generally QC analytics and biocharacterization of viral vector and supporting starting biomaterials, all of which could be outsourced costs or could be developed and managed in-house.
This Fierce Biotech Webinar features Nelson Carramanzana from Kite Pharma, where he provides insight into CoGs, lifecycle, and supply chain costs for these expensive cell therapies.
